

Analyst
John Hester 612 8224 2871

Authorisation
Tanushree Jain 612 8224 2849

Cyclopharm (CYC)

Recruitment Commences

Speculative

Refer to key risks on page 3 and Biotechnology Risk Warning on page 5. Speculative securities may not be suitable for retail clients.

Recommendation

Buy (unchanged)

Price

\$0.74

Valuation

\$1.13 (unchanged)

Risk

Speculative

GICS Sector

Healthcare Equipment and Services

Expected Return

Capital growth	52.7%
Dividend yield	1.4%
Total expected return	54.1%

Company Data & Ratios

Enterprise value	\$40.6m
Market cap	\$50.6m
Issued capital	68.4m
Free float	94%
Avg. daily val. (52wk)	\$17K
12 month price range	\$0.71 - \$1.20

Price Performance

	(1m)	(3m)	(12m)
Price (A\$)	0.09	0.13	0.13
Absolute (%)	-1.61	-26.80	-26.80
Rel market (%)	-1.77	-24.29	-29.89

Absolute Price



SOURCE: IRESS

First Patients Enrolled in US Pivotal

Cyclopharm has now completed the recruitment of the first two patients in its US pivotal study. Both patients were seen at Washington University, St Louis Missouri. Both were lung transplant patients – which in itself is highly significant, while the delivery of the Technegas and subsequent imaging were completed without incident.

Technegas is a lung imaging system that has been delivered safely to more than 3.6m patients in 55 countries outside of the US. Due to its extensive use, the probability of a significant mishap or unforeseen clinical trial result remains very low. Technegas is the standard of care for diagnosis of pulmonary embolism (PE) in patients contraindicated for CT scan.

It appears Pulmonologist clinicians involved in the trial have more expansive plans for this system than diagnosis of pulmonary embolism alone and this is highly encouraging. If successful in this pivotal study, the FDA is likely to indicate Technegas for structural lung ventilation which vastly expands the scope of use and potentially the revenue base. To date the vast majority of Technegas use has been for diagnosis of PE.

Over the next few days the company expects both Duke University Hospital and Emory University to commence patient enrolment. The next catalyst for the stock is completion of the first 40 patients which is the interim reporting point to the FDA. The company is expected to release the data package from the first 40 patients in due course. The remainder of this note contains an overview of the trial design.

We expect enrolment of these patients together with submission of the data package to be completed by 31 March 2018. Patient enrolment in the trial was identified as a key risk to meeting long term revenue and earnings targets, hence the successful completion of the first two patients is a small but significant step. There are no changes to earnings estimates or valuation. We retain our Speculative Buy recommendation and valuation of \$1.13.

Earnings Forecast

December Year End	FY16	FY17e	FY18e	FY19e
Revenues	14.4	13.7	14.6	16.7
EBITDA \$m	2.0	0.1	-0.5	0.8
NPAT (underlying) \$m	1.1	-0.1	-0.7	0.5
NPAT (reported) \$m	0.8	-0.1	-0.7	0.5
EPS underlying (cps)	1.9	-0.1	-1.0	0.7
EPS growth %	-60%	-105%	904%	-166%
PER (x)	0.4	-7.3	-0.7	1.1
FCF yield (%)	-3%	-1%	-3%	-1%
EV/EBITDA (x)	20.4	478.2	-74.1	50.2
Dividend (cps)	1.0	1.0	1.0	1.0
Franking	0%	0%	0%	0%
Yield %	1.4%	1.4%	1.4%	1.4%
ROE %	15.2%	-0.3%	-4.1%	3.9%

SOURCE: BELL POTTER SECURITIES ESTIMATES

Trial Design Aimed At Approval

The key points for the current study (known as CYC009) study are:

- 240 patients;
- The trial has a Special Protocol Assessment (SPA). An SPA agreement indicates concurrence by the FDA with the adequacy and acceptability of specific critical elements of overall protocol design. These elements are critical to ensuring that the trial conducted under the protocol has the potential to support a future application for approval;
- Interim reporting on first 40 patients;
 - Participants on the trial will undergo two separate imaging studies – the first using Xenon¹³³, the second using Technegas;
 - Physicians will be blinded as to the patient identification and will assess both sets of images, assigning a ventilation function score to each image;
 - Investigators will compare the independently assessed scores for each image and each patient;
 - The primary outcome is the percent agreement between Technegas and Xe¹³³ blinded ventilation assessments;
 - The imaging technology for this trial will be the relatively low tech planar imaging (2 dimensional images). This was selected because it is the standard of care in the US for lung imaging with nuclear medicine; and
 - Trial is open to all comers, regardless of co-morbidities, medication or prior treatment.

This is a non-inferiority trial design which we regard as pragmatic – it achieves the bare minimum in order to gain approval. By comparison a previous 750 patient study was benchmarked to the higher standard of diagnostic equivalence (i.e. of PE) with many exclusion criteria – consequently recruitment rates were abysmal.

We expect the trial will now recruit rapidly following these first two patients. The trial is open to all comers, not just emergency room patients, or patients with suspected PE. Patients with any pulmonary complaint may be admitted to the trial, hence this should remove a significant barrier to patient recruitment.

The treatment of the first patients was later than expected, however, there should be an ample number of patients to allow for rapid recruitment. The company hopes to have an additional 6 sites recruiting patients by the end of November. Duke University and Emory University should commence enrolments within days. Up to 15 sites may eventually be added.

There are no changes to earnings estimates or valuation. We retain our buy recommendation and price target of \$1.13.

Cyclopharm Limited

A Growing Medical Device Company

Cyclopharm is a medical device company operating in the specialist field of nuclear medicine. The main revenue driver is Technegas - a system indicated for functional lung imaging. The primary use of Technegas is diagnosis of pulmonary embolism in patients contra indicated for a CT scan.

Diagnosis of pulmonary embolism and other pulmonary conditions requiring structural analysis of the lungs via Technegas is a safer, more accurate, cost effective solution for thousands of patients around the world each year.

Imaging for pulmonary disease and the use of nuclear medicine is standard practice around the world, hence the products manufactured by the company fit within accepted medical practice. Cyclopharm is therefore not a biotechnology stock or drug developer, rather its status as a medical device company is well established.

BUSINESS MODEL

The Technegas system has two major components being the Technegas Generator and its consumables. The generators sell for between \$26K - \$50K and the single use consumables sell for between \$70 - \$100 per patient. The consumables generate the majority of revenues.

In Australia, NZ, Canada and Germany the company performs its own distribution direct to hospital customers. In other jurisdictions it uses a distributor model.

End users are generally the Nuclear Medicine departments of large hospitals in each of the 55 countries (excluding the US) around the world where Technegas is approved. The company's head office is in Sydney along with its manufacturing/assembly and R&D facilities.

ENTRY TO US MARKET

The medium term catalyst for Cyclopharm is entry into the US market. It has now commenced a pivotal clinical study in the US which we expect will lead to FDA approval of the Technegas system. As is normally the case, the US market should attract premium pricing in addition to being the largest, best funded medical market in the world. Following FDA approval, the revenue base in the US is expected to rapidly exceed cumulative revenues from all other markets. In most other markets where Technegas has been introduced, the competing radiopharmaceutical has been withdrawn from sale. The most recent example of this was in Canada which is now the largest single market for Technegas.

The short term catalyst should be the release of clinical trial data on the first 40 patients in the US trial which the company is required to submit to the FDA. Technegas has been used in more than 3.6m patient exams with no known side effects. The product is known to be safe and produce high quality images for analysis and accordingly we believe the clinical risk associated with the trial is far lower than with the drug developer. First substantial revenues from the US market are expected in calendar 2019.

The major key risk in the trial is patient recruitment. Cyclopharm has previously attempted to recruit patients into a much larger study and made virtually no progress. The flaws in the trial design were identified and the current trial is vastly different with a primary end point of non-inferiority.

Table 1 - Financial summary

Profit & Loss (A\$m)	FY15	FY16	FY17e	FY18e	FY19e
Year Ending June					
US Revenues	-	-	-	-	1.2
ROW Revenues	12.5	14.4	13.7	14.6	15.5
Total Revenues	12.5	14.4	13.7	14.6	16.7
COGS	-2.7	-3.5	-2.7	-2.9	-3.3
Gross profit	9.8	10.9	11.0	11.7	13.3
GP margin	78.6%	75.5%	80.0%	80.0%	80.0%
Operating expenses	6.9	7.8	7.9	8.2	10.5
Clinical trial costs	0.7	1.1	3.0	4.0	2.0
EBITDA	2.3	2.0	0.1	-0.5	0.8
Depreciation and Amortisation	-0.1	-0.1	-0.2	-0.2	-0.2
EBIT	2.1	1.9	-0.1	-0.7	0.7
EBIT margin	17.2%	13.1%	-0.5%	-4.8%	4.3%
Net other income	0.1	0.0	0.0	0.0	0.0
Pre tax profit	2.2	1.9	-0.1	-0.7	0.7
Tax expense	0.7	-0.8	0.0	0.0	-0.2
NPAT- normalised	2.9	1.1	-0.1	-0.7	0.5
Net abnormal items	1.9	(0.3)	-	-	-
Reported NPAT	4.8	0.8	-0.1	-0.7	0.5
Cashflow (A\$m)	FY15	FY16	FY17e	FY18e	FY19e
Gross cashflow	1.9	1.3	0.4	-0.7	0.6
Net interest	0.0	0.0	0.0	0.0	0.0
Tax paid	0.1	-0.6	0.0	0.0	-0.2
Operating cash flow	4.2	0.7	0.4	-0.7	0.4
Maintenance capex	0.0	-1.8	-0.2	-0.2	-0.2
Other capitalised intangibles	-0.6	-0.4	-0.4	-0.4	-0.4
Free cash flow	3.5	-1.6	-0.2	-1.3	-0.2
Business acquisitions	0.0	0.0	0.0	0.0	0.0
Proceeds from issuance	0.0	0.0	7.0	0.0	0.0
Movement in debt	0.0	-0.2	0.0	0.0	0.0
Dividends paid	-0.3	-0.6	-0.6	-0.7	-0.7
Change in cash held	3.2	(2.3)	6.2	(2.0)	(0.8)
Cash at beginning of period	0.0	6.4	4.6	10.8	8.8
Cash at year end	6.4	4.6	10.8	8.8	8.0
Balance Sheet (A\$m)	FY15	FY16	FY17e	FY18e	FY19e
Cash	6.4	4.6	10.8	8.8	8.0
Receivables	4.4	3.7	3.6	3.8	4.4
Inventory	2.2	2.6	2.8	2.9	3.0
Other current assets	-	0.1	0.1	0.1	0.1
Property, Plant and Equipment	0.6	2.3	2.4	2.4	2.5
Intangible assets	1.3	1.7	2.1	2.5	2.8
Deferred tax assets	1.5	1.2	1.2	1.2	1.2
Total assets	16.5	16.3	22.9	21.7	22.0
Trade payables	1.8	2.8	3.0	3.2	3.7
Debt	0.2	-	-	-	-
Tax payable	0.5	-	-	-	0.0
Other liabilities	-	0.2	0.2	0.2	0.2
Deferred income tax liability	-	-	-	-	-
Provisions	1.0	1.0	1.0	1.1	1.1
Total Liabilities	3.4	3.9	4.3	4.5	5.0
Net Assets	13.1	12.4	18.6	17.2	17.0
Share capital	15.0	15.0	22.0	22.0	22.0
Retained earnings	(2.5)	(2.3)	(3.0)	(4.4)	(4.6)
Reserves	0.7	(0.3)	(0.3)	(0.4)	(0.4)
Shareholders Equity	13.1	12.4	18.6	17.2	17.0

Valuation Ratios (A\$m)	FY15	FY16	FY17e	FY18e	FY19e
Reported EPS (cps)	8.1	1.4	-0.1	-1.0	0.7
Normalised EPS (cps)	4.9	1.9	-0.1	-1.0	0.7
EPS growth (%)	151%	-60%	-105%	904%	-166%
PE(x)	0.0	0.4	-7.3	-0.7	1.1
EV/EBITDA (x)	17.7	20.4	478.2	-74.1	50.2
EV/EBIT (x)	18.9	21.5	-624.3	-58.2	61.5
NTA (cps)	19.8	24.5	30.4	28.2	28.0
P/NTA (x)	0.0	0.0	0.0	0.0	0.0
Book Value (cps)	22.0	20.8	27.4	25.2	24.9
Price/Book (x)	0.0	0.0	0.0	0.0	0.0
DPS (cps)	1.0	1.0	1.0	1.0	1.0
Payout ratio %	20%	52%	0%	0%	0%
Dividend Yield %	1.4%	1.4%	1.4%	1.4%	1.4%
Franking %	-73%	0%	0%	0%	0%
FCF yield %	5%	-3%	-1%	-3%	-1%
Net debt/Equity	0%	0%	0%	0%	0%
Net debt/Assets	0%	0%	0%	0%	0%
Gearing	net cash	net cash	net cash	net cash	net cash
Net debt/EBITDA (x)	n/a	n/a	n/a	n/a	n/a
Interest cover (x)	n/a	n/a	n/a	n/a	n/a

PAS Unit sales	FY15	FY16	FY17e	FY18e	FY19e
Europe	3,820	3,935	4,053	4,174	4,299
Growth	4%	3%	3%	3%	3%
USA	-	-	-	-	40
Growth	0%	0%	0%	0%	0%
Total Patient Admin Sets Sold	3,820	3,935	4,053	4,174	4,339
Average revenue per sale A\$'000	2,656	2,845	3,047	3,264	3,497

SOURCE: BELL POTTER SECURITIES ESTIMATES

Recommendation structure

Buy: Expect >15% total return on a 12 month view. For stocks regarded as 'Speculative' a return of >30% is expected.

Hold: Expect total return between -5% and 15% on a 12 month view

Sell: Expect <-5% total return on a 12 month view

Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet.

Such investments may carry an exceptionally high level of capital risk and volatility of returns.

Research Team

Staff Member	Title/Sector	Phone	@bellpotter.com.au
TS Lim	Head of Research	612 8224 2810	tslim
Industrials			
Sam Haddad	Industrials	612 8224 2819	shaddad
John O'Shea	Industrials	613 9235 1633	joshea
Chris Savage	Industrials	612 8224 2835	csavage
Jonathan Snape	Industrials	613 9235 1601	jsnape
Tim Piper	Industrials	612 8224 2825	tpiper
John Hester	Healthcare	612 8224 2871	jhester
Tanushree Jain	Healthcare/Biotech	612 8224 2849	tnjain
Financials			
TS Lim	Banks/Regionals	612 8224 2810	tslim
Lafitani Sotiriou	Diversified	613 9235 1668	Isotiriou
Resources			
Peter Arden	Resources	613 9235 1833	parden
David Coates	Resources	612 8224 2887	dcoates
Duncan Hughes	Resources	618 9326 7667	dhughes
Associates			
James Filius	Associate Analyst	613 9235 1612	jfilius
Alex McLean	Associate Analyst	612 8224 2886	amclean

Bell Potter Securities Limited

ACN 25 006 390 7721

Level 38, Aurora Place

88 Phillip Street, Sydney 2000

Telephone +61 2 9255 7200

www.bellpotter.com.au

The following may affect your legal rights. Important Disclaimer:

This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. In Hong Kong this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client's financial situation, particular needs and investment objectives ('relevant personal circumstances'), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document. While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued. Except insofar as liability under any statute cannot be excluded, Bell Potter Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person.

Disclosure of interest:

Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document. Disclosure: Bell Potter Securities acted as Lead manager of the company's 2017 Capital Raising and received fees for that service.

Biotechnology Risk Warning:

The stocks of biotechnology companies without strong revenue streams from product sales or ongoing service revenue should always be regarded as speculative in character. Since most biotechnology companies fit this description, the speculative designation also applies to the entire sector. The fact that the intellectual property base of a typical biotechnology company lies in science not generally regarded as accessible to the layman adds further to the riskiness with which biotechnology investments ought to be regarded. Stocks with 'Speculative' designation are prone to high volatility in share price movements. Clinical and regulatory risks are inherent in biotechnology stocks. Biotechnology developers usually seek US FDA approval for their technology which is a long and arduous three phase process to prove the safety, effectiveness and appropriate application or use of the developed drug and even after approval a drug can be the subject of an FDA investigation of subsequently discovered possible links between the drug and other diseases not previously diagnosed. Furthermore, the Australian exchange listed biotechnology sector is subject to influence by the global biotechnology sector, particularly that in the USA. Consequently, Australian exchange listed biotechnology stocks can experience sharp movements, both upwards and downwards, in both valuations and share prices, as a result of a re-rating of the sector both globally and in the USA, in particular. Investors are advised to be cognisant of these risks before buying such a stock including Cyclopharm Limited. For a list of risks specific to Cyclopharm please refer to Page 3 of this note.

ANALYST CERTIFICATION:

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.